Adaptive Biotechnologies

Forecast & Rating9 analysts currently cover Adaptive Biotechnologies, with about 88.9% giving a positive rating — meaning they expect the stock to rise. The average price target is $27.44, about 4.6% downside from the current price of $28.77. Price targets range from $21.00 to $35.00 — a wide spread, showing clear disagreement over just how much Adaptive Biotechnologies can rise. Historically, about 34.7% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Adaptive Biotechnologies closely still see room for the stock to rise. Data as of Sep 29, 2026; for reference only and not investment advice.